Skip to content

Comparison of the Efficacy Between Liposomal Bupivacaine and Ropivacaine in Saphenous Nerve Block for Total Knee Arthroplasty

Comparison of the Efficacy Between Liposomal Bupivacaine and Ropivacaine in Saphenous Nerve Block for Total Knee Arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126370
Enrollment
Unknown
Registered
2026-06-08
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Interventions

Observation group:The observation group was given liposomal bupivacaine injection.
Control group:The control group was given ropivacaine hydrochloride injection.

Sponsors

Zhenxiong County People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Meet the surgical indications for total knee arthroplasty and scheduled for unilateral elective surgery; 2. ASA physical status classification Grade I–III; 3. No contraindications to peripheral nerve block; 4. No history of allergy to the medications used in this study; 5. Both patients and their families gave informed consent and signed the informed consent form. 6. Able to cooperate with postoperative pain scoring, functional exercises, and follow-up work.

Exclusion criteria

Exclusion criteria: 1.Combined with severe dysfunction of vital organs such as the heart, liver and kidney; 2.Abnormal coagulation function or infection at the puncture site; 3.Complicated with lower limb neuromuscular lesions and motor dysfunction; 4.History of chronic pain or long-term use of opioids; 5.Unable to cooperate with pain scoring and postoperative follow-up. 6. Has a mental illness or cognitive dysfunction, unable to communicate normally.

Design outcomes

Primary

MeasureTime frame
VAS score;Dosage of rescue analgesic drugs at 24 h, 48 h and 72 h postoperatively;

Secondary

MeasureTime frame
Adverse reaction incidence rate;

Countries

China

Contacts

Public ContactLin Lungang

Zhenxiong County People's Hospital

56753627@qq.com+86 134 6621 1177

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026